aminoquinoline

(redirected from 8-Aminoquinoline)
Also found in: Wikipedia.

aminoquinoline

 [ah-me″no-kwin´o-lēn]
a heterocyclic compound derived from quinoline by the addition of an amino group; the 4-aminoquinoline and 8-aminoquinoline derivatives are groups of antimalarial agents.

aminoquinoline

/ami·no·quin·o·line/ (ah-me″no-kwin´o-lēn) a heterocyclic compound derived from quinoline by the addition of an amino group; the 4-aminoquinoline and 8-aminoquinoline derivatives constitute classes of antimalarials.
References in periodicals archive ?
Tafenoquine is an investigational 8-aminoquinoline derivative with activity against the P.
CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine.
The endoperoxide OZ439, currently in Phase II clinical trials, and a new 8-aminoquinoline, NPC-1161B, also demonstrated transmission-blocking potential.
A new 8-aminoquinoline tafenoquine is on clinical trial as a potential replacement for primaquine to treat Plasmodium vivax malaria (Shanks 2001) and holds promise as a prophylactic against Plasmodium falciparum (Shanks 2001).
Tefenoquine, which is an 8-aminoquinoline, has activity against blood-stage and liver-stage malaria parasite.
These include an 8-aminoquinoline derivative under pre-clinical evaluation for the treatment of malaria, leishmania and pneumocystis pneumonia.
Primaquine, an 8-aminoquinoline was covalently coupled onto oxidized gum arabic via imine bond and simultaneously fabricated into microspheres of less than 2 [micro]m in size by heat denaturation in a reverse emulsion of 1:1 light paraffin oil and toluene stabilized by sorbitan sesquioleate as the surfactant.
Key words: gum arabic, polysaccharide, periodate oxidation, microspheres, drug delivery, primaquine, 8-aminoquinoline, sustained release, controlled release, polymer-drug conjugate.
Primaquine, an 8-aminoquinoline and some of its derivatives are potent drugs in the treatment of malaria as well as other parasitic diseases such as Leishmaniasis (1-8).
Mass administration of an antimalarial drug combining 4-aminoquinoline and 8-aminoquinoline in Tanganyika.
Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphtho-quinones.